Skip to main content
. Author manuscript; available in PMC: 2011 Jul 15.
Published in final edited form as: Clin Cancer Res. 2010 Jul 6;16(14):3628–3638. doi: 10.1158/1078-0432.CCR-09-3022

Figure 2.

Figure 2

A) Differential effects of rapamycin versus NVP-BEZ235 on intracellular signaling in RCC cells treated with DMSO, rapamycin (100nM), or NVP-BEZ235 (250nM) for 24 hours and then lysed and analyzed by Western blot. B) Superior inhibition of RCC cell proliferation by NVP-BEZ235 as compared with rapamycin. Proliferation is expressed as the percent viable cells in the NVP-BEZ235 (B) or rapamycin (R) treated cultures as compared with DMSO (0) treated cells. Each bar represents the mean of three independent experiments (error bar = 1 S.D.).